Catheter PrecisionNYSE American: VTAK

FORT MILL, SC / ACCESSWIRE / October 23, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company focused on electrophysiology products announced that there will be two presentations showcasing the VIVO technology at the International Society for Cardiac Robotic Navigation Meeting (SCRN) October 28-29 in Lisbon, Portugal. The 2024 program highlights VIVO in the presentations.

FORT MILL, SC / ACCESSWIRE / October 15, 2024 / Catheter Precision, Inc. (NYSE/American:VTAK), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 15th International Symposium on Catheter Ablation Techniques (ISCAT) from October 16 - 18 in Paris, France. ISCAT is a biannual European meeting that focuses on new and emerging catheter ablation technologies, techniques, and study data for both atrial and ventricular arrhythmias.

FORT MILL, SC / ACCESSWIRE / September 24, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American), a company engaged in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced that has received notification of the issuance of its first LockeT patent in the country of China. Locket is a suture retention device used in the closure of percutaneous catheter access sites during any number of catheter procedures including electrophysiology, structural heart, and vascular surgery procedures.

FORT MILL, SC / ACCESSWIRE / September 18, 2024 / Catheter Precision, Inc. (the"Company") (NYSE American:VTAK), a US based medical device pioneering electrophysiology products, announced that it has completed a distribution agreement for LockeT with Dubai based company Forum Medical. The distribution agreement also includes partnerships with additional distributors in the Middle East, expanding LockeT distribution to Georgia, Uzbekistan and Kazakhstan.

FORT MILL, SC / ACCESSWIRE / September 11, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company in the growing field of cardiac electrophysiology, announced its first purchase order from the pacific northwest territory. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT.

FORT MILL, SC / ACCESSWIRE / September 4, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, announced its first purchase order from a hospital in the greater Chicago area. As previously announced, the company has recently expanded their US sales and clinical team in preparation for the national product launch of LockeT which includes the Chicago region.

FORT MILL, SC / ACCESSWIRE / September 3, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a U.S.-based innovative medical device company, today announced the closing of its previously announced public offering of 805,900 common stock units, including 458,623 common stock units issued upon exercise of the underwriters' over-allotment option, priced at a public offering price of $1.00 per unit, and 2,773,000 pre-funded warrant units, priced at a public offering price of $0.9999 per unit. Each common stock unit and pre-funded warrant unit consists of one share of common stock (or, in lieu of common stock, a pre-funded warrant to purchase one share of common stock at an exercise price of $0.0001), one warrant to purchase one share of common stock that expires on the six month anniversary of the date of issuance (a "Series H Warrant"), one warrant to purchase one share of common stock that expires on the eighteen month anniversary of the date of issuance (a "Series I Warrant"), and one warrant to purchase one share of common stock that expires on the five year anniversary of the date of issuance (a "Series J Warrant").

FORT MILL, SC / ACCESSWIRE / August 14, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a MedTech company pioneering products in the growing field of cardiac electrophysiology, including its VIVO™ and LockeT product(s), releases Q2 Financials and Operational Report. Operational highlights include the following: First commercial sales of LockeT in the US 14 new sales and clinical hires at various stages of training completion Larger number of US hospitals than projected have confirmed product interest and have scheduled evaluations 23 hospitals for LockeT 10 hospitals for VIVO VIVO product evaluation started at large volume center in Italy New LockeT publication in the Journal of Cardiovascular Electrophysiology Catheter Precision is attending the Kansas City Heart Rhythm Society Conference (KCHRS) in Kansas City August 17 and 18, 2024 Completion of the VIVO EU Registry in June 2024 2024 Second Quarter Financial Results are as follows: Total assets at June 30, 2024, were $26 million Total cash on position at June 30, 2024 was $16 thousand, and $330 thousand at August 12, 2024 Total revenues for the three and six months ended June 30, 2024, were $93 thousand and $175 thousand, respectively Shareholders' equity as of June 30, 2024, was $14.3 million Net loss for the three and six months ended June 30, 2024, was ($4.2) million and ($6.9) million, respectively LockeT sales for the three and six months ended June 30, 2024, were $38 thousand for both periods.

FORT MILLS, SC / ACCESSWIRE / July 15, 2024 / Catheter Precision, Inc. (NYSE American:VTAK), a US based innovative medical device company, announced today that its previously announced 1-for-10 reverse stock split of its common stock became effective at 12:01 A.M. Eastern Time, on July 15, 2024.